UK markets closed
NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.70 +0.68 (+0.87%) GOLD FUTURES
2,390.00 +30.10 (+1.28%) DOW
39,834.79 +276.68 (+0.70%) Bitcoin GBP
51,662.45 +3,237.18 (+6.68%)
PTCT May 2024 35.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:29PM EDT. Market open.
| Previous close | 1.7500 |
| Open | 0.6900 |
| Bid | 0.0000 |
| Ask | 0.6500 |
| Strike | 35.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.6900 - 1.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1k |
PR NewswirePTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
Investor's Business DailyPTC Therapeutics Stock Sees IBD RS Rating Climb To 72
PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
© 2024 Yahoo. All rights reserved.